Trial Profile
A PHASE II STUDY: UNOPERABLE NON NON SQUAMOUS NON SMALL CELL LUNG CANCER METRONOMIC BIOCHEMOTHERAPY WITH WEEKLY CISPLATIN, DAILY ORAL ETOPOSIDE AND BEVACIZUMAB (mPEBev regimen).
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 31 Oct 2011
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Cisplatin; Etoposide
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- 28 Jul 2011 New trial record